Overview

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Status:
COMPLETED
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Pure Biologics S.A.
Collaborator:
Presage Biosciences